文献速递冠心病心力衰竭与心肌病

CXCR4阻断通过增强调节性T细胞动员与免疫调节功能促进心肌梗死后组织修复

C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function.
PubMed 文献 · Circulation · 2019-01-01

该研究在小鼠再灌注心肌梗死模型中探究CXCR4拮抗剂POL5551的治疗潜力及机制,发现其可增强梗死边缘区血管新生、减小瘢痕、减轻左室重构和收缩功能障碍,效应依赖脾脏和调节性T细胞;在猪模型中类似物POL6326减少梗死体积并改善射血分数。

要点

  • CXCR4拮抗剂POL5551在再灌注心梗小鼠中促进修复,效应依赖脾脏和Treg细胞。
  • POL5551动员Treg进入外周血并聚集于梗死区,经Treg抑制单核/巨噬细胞炎症基因表达。
  • 临床阶段类似物POL6326在猪再灌注心梗中减少梗死体积并改善左室射血分数。

核心结论

  • CXCR4阻断是心肌梗死后有前景的治疗策略。
  • 树突状细胞致敏的脾脏Treg细胞是POL5551治疗效应的核心介导者。
  • 通过增强体内Treg细胞功能可促进梗死修复。

研究设计与样本

  • 小鼠再灌注心肌梗死模型,使用POL5551腹腔注射(8 mg/kg,第2、4、6、8天)。
  • 采用细胞清除与过继转移策略,包括Rag1敲除小鼠、DEREG小鼠和CD11c-Cre iDTR小鼠。
  • 猪再灌注心肌梗死模型,静脉输注POL6326(3 mg/kg,第4、6、8、10天),用系列对比增强磁共振成像评估。

主要发现

  • 野生型小鼠POL5551注射后28天梗死边缘区血管新生增强、瘢痕减小、左室重构和收缩功能障碍减轻。
  • 脾切除野生型小鼠、Rag1敲除小鼠和Treg细胞清除的DEREG小鼠中治疗效应消失。
  • 将POL5551处理梗死DEREG小鼠的脾脏Treg细胞移植给梗死脾切除野生型小鼠可转移治疗效应。
  • POL5551注射动员Treg细胞进入外周血并增强其在梗死区聚集;中性粒细胞、单核细胞和淋巴细胞动员动力学相似但心脏募集未受影响。
  • POL5551经Treg细胞减弱梗死区单核细胞和巨噬细胞的炎症基因表达。

临床怎么用

  • CXCR4阻断可能作为心肌梗死后促进组织修复的药物治疗策略。
  • 治疗效应依赖脾脏和Treg细胞,提示Treg功能是潜在干预靶点。
  • 临床阶段类似物POL6326在猪模型显示转化潜力,支持进一步临床研究。

局限性

  • 机制研究主要在小鼠模型中进行,人体证据尚缺。
  • 猪模型样本量和统计细节未在摘要中报告。
  • POL5551与POL6326的剂量方案在动物模型中使用,尚未确立人体剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute myocardial infarction (MI) elicits an inflammatory response that drives tissue repair and adverse cardiac remodeling. Inflammatory cell trafficking after MI is controlled by C-X-C motif chemokine ligand 12 (CXCL12) and its receptor, C-X-C motif chemokine receptor 4 (CXCR4). CXCR4 antagonists mobilize inflammatory cells and promote infarct repair, but the cellular mechanisms are unclear. METHODS: We investigated the therapeutic potential and mode of action of the peptidic macrocycle CXCR4 antagonist POL5551 in mice with reperfused MI. We applied cell depletion and adoptive transfer strategies using lymphocyte-deficient Rag1 knockout mice; DEREG mice, which express a diphtheria toxin receptor-enhanced green fluorescent protein fusion protein under the control of the promoter/enhancer region of the regulatory T (Treg) cell-restricted Foxp3 transcription factor; and dendritic cell-depleted CD11c-Cre iDTR mice. Translational potential was explored in a porcine model of reperfused MI using serial contrast-enhanced magnetic resonance imaging. RESULTS: Intraperitoneal POL5551 injections in wild-type mice (8 mg/kg at 2, 4, 6, and 8 days) enhanced angiogenesis in the infarct border zone, reduced scar size, and attenuated left ventricular remodeling and contractile dysfunction at 28 days. Treatment effects were absent in splenectomized wild-type mice, Rag1 knockout mice, and Treg cell-depleted DEREG mice. Conversely, treatment effects could be transferred into infarcted splenectomized wild-type mice by transplanting splenic Treg cells from POL5551-treated infarcted DEREG mice. Instructive cues provided by infarct-primed dendritic cells were required for POL5551 treatment effects. POL5551 injections mobilized Treg cells into the peripheral blood, followed by enhanced Treg cell accumulation in the infarcted region. Neutrophils, monocytes, and lymphocytes displayed similar mobilization kinetics, but their cardiac recruitment was not affected. POL5551, however, attenuated inflammatory gene expression in monocytes and macrophages in the infarcted region via Treg cells. Intravenous infusion of the clinical-stage POL5551 analogue POL6326 (3 mg/kg at 4, 6, 8, and 10 days) decreased infarct volume and improved left ventricular ejection fraction in pigs. CONCLUSIONS: These data confirm CXCR4 blockade as a promising treatment strategy after MI. We identify dendritic cell-primed splenic Treg cells as the central arbiters of these therapeutic effects and thereby delineate a pharmacological strategy to promote infarct repair by augmenting Treg cell function in vivo.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wang Y, Dembowsky K, Chevalier E, et al. C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function. Circulation. 2019. PMID: 30696265. doi:10.1161/CIRCULATIONAHA.118.036053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。